AXSM - יחס חוב להיוון בספרים Axsome

Axsome Therapeutics (AXSM) is shifting toward active sales, diversifying risks across various neurological projects, although geopolitics may disrupt supply chains and international trials. The market price action of the company's securities is recorded below, with the key metric standing at 2.57. The business relies on developing innovative therapies for depression and migraine, which are becoming fundamental standards in modern psychiatry.

This ratio measures the degree of financial leverage by comparing total accounts payable to the book value of equity to assess default risks. Analyzing the history of leverage relative to capitalization reveals that the active commercialization of the neurology R&D pipeline allows Axsome Therapeutics (AXSM) to effectively finance new drug launches while maintaining a stable capital structure.